Partial
Partially Aligned
Patient Risk:
Low
Summary
Partially aligned: the tablet (oral pill) dosage-form claim is supported by the provided label section, but claims that Imbruvica is available as a subcutaneous injection (including prefilled syringe and single-dose vial administration) are not supported because the provided label section lists only capsules, tablets, and oral suspension.
Category Scores
Accurate Statements
Imbruvica is available in an oral tablet form for patients to take as a pill.
Supported by Section 3 (DOSAGE FORMS AND STRENGTHS): Tablets are listed with multiple strengths (e.g., 140 mg, 280 mg, 420 mg).
Unsupported Statements
Imbruvica is available in a subcutaneous injection form.
Not supported by the provided label Section 3: only Capsules, Tablets, and Oral Suspension are listed; no injection/subcutaneous dosage form is listed.
The subcutaneous injection form of Imbruvica is administered under the skin using a prefilled syringe.
Not supported: no subcutaneous injection dosage form and no prefilled syringe instructions are present in the provided label content.
The subcutaneous injection form of Imbruvica is administered under the skin using a single-dose vial.
Not supported: no subcutaneous injection dosage form and no single-dose vial instructions are present in the provided label content.
Contradictions
Low
AI Statement
Imbruvica is available in a subcutaneous injection form.
Label Reference
Section 3 (DOSAGE FORMS AND STRENGTHS) lists only Capsules, Tablets, and Oral Suspension; does not list an injection/subcutaneous dosage form.
Important Omissions
Safety Assessment
Potential Patient Risk:
Low
The evaluation concerns dosage-form/administration route claims not supported by the provided label section; no boxed warnings, contraindications, or safety statements were assessed in the provided claims.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Incorrect dosage-form claims: subcutaneous injection (including prefilled syringe and single-dose vial administration) is not supported by the provided label Section 3.
Suggested Improvement
Remove or revise the subcutaneous injection/pre-filled syringe/single-dose vial claims and limit dosage-form statements to those listed in the provided label content (capsules, tablets, oral suspension).